Paliroden

DB05454InvestigationalSmall molecule

Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and... It is indicated for use in Alzheimer's Disease and Parkinson’s.

Mechanism: SR 57667 may be an irreversible MAOB inhibitor.
Curator reviewed
Primary indication: Investigated for use/treatment in Alzheimer's disease and Parkinson's disease.Curator reviewed
Formula / weight: C₂₆H₂₄F₃N · 407.48 g/mol (avg)
Code names: SR 57667 · SR5-7667B

Resolves to

Compound

UNII17VJ76L90TCAS188396-77-2ChEMBLCHEMBL2107767PubChem11567682

Structure

InChIKeyCNEWKIDCGDXBDE-UHFFFAOYSA-NSMILESFC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC=C(C=C2)C2=CC=CC=C2)CC1

Targets

P42262GRIA2

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Paliroden, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account